Ginkgo Bioworks Holdings DNA
NYSE DNA
$6.93 -0.02 (-0.29%)
As of: Sep 4, 2026 · 11:51 AM EDT

Ginkgo Bioworks Holdings (DNA) Equity Income (2020 - 2026)

Analysis

Ginkgo Bioworks Holdings (DNA) Equity Income (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Income (Qtr)
1 Vertex Pharmaceuticals 140.22 Bn 132.37 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 86.04 Bn 78.05 Bn 3.93 Bn -
3 Argenx Se 63.70 Bn 58.52 Bn 1.37 Bn -
4 Moderna 57.56 Bn 52.42 Bn 52.00 Mn -
5 Revolution Medicines 44.05 Bn 44.05 Bn - -
6 BeOne Medicines 40.16 Bn 35.06 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.63 Bn 32.32 Bn 992.69 Mn -
8 Royalty Pharma 28.63 Bn 27.79 Bn - 4.08 Mn
9 Insmed 27.73 Bn 26.57 Bn 358.27 Mn -
10 Ginkgo Bioworks Holdings 430.38 Mn 345.84 Mn 18.44 Mn -4.67 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -4.67 Mn
Dec 31, 2023 -1.12 Mn
Jun 30, 2023 -67,000.00
Mar 31, 2023 -1.45 Mn
Dec 31, 2022 10.00 Mn
Sep 30, 2022 -22.71 Mn
Jun 30, 2022 -10.17 Mn
Mar 31, 2022 -20.89 Mn
Dec 31, 2021 -4.66 Mn
Sep 30, 2021 -39.65 Mn
Jun 30, 2021 -4.35 Mn
Mar 31, 2021 -28.62 Mn
Dec 31, 2020 1.76 Mn
Sep 30, 2020 -237,000.00